• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Rajiv Anand, MD; Stephen D. Nightingale, MD; Richard H. Fish, MD
Dallas, Tex

Thomas J. Smith, MD
Boston, Mass

Paul Ashton, PhD
Lexington, Ky

Arch Ophthalmol. 1994;112(1):20-21.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

We appreciate the insightful remarks of Dr Spaide and of Dr Geier and colleagues regarding the use of the ganciclovir-containing intraocular device for the control of progressive CMV retinitis. The issue that both of these letters raise is exceedingly important regarding survival of patients with AIDS-associated CMV retinitis.

Our report presented the results of an initial pilot study regarding the safety and efficacy of a ganciclovircontaining device that would deliver the drug intraocularly over a long period of time.¹ We would like to emphasize that the study was not designed to evaluate the effect on patients' survival. We recruited patients who had active, progressive CMV retinitis in one or both eyes. Patients with symptomatic, systemic CMV infection or visual acuity of less than 20/200 due to macular scarring or optic nerve involvement were excluded. Our only end point was the determination of the effect of the slow . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?